GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alzex Neuropharma TRRI · USD

Materials · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 5 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Alzex Neuropharma

Its shares trade under the ticker TRRI. It has been listed since 11 July 2001.

Trinity Resources, Inc. engages in the exploration and development of natural resource interests. The company is headquartered in Henderson, Nevada. The company went IPO on 2001-07-11. The firm is engaged in research and development targeting treatments of brain diseases. The company is also focused on chemical development of its new drugs dedicated to the symptomatic treatment of Alzheimer’s Disease but can be applied to other neurological diseases due to its platform technology.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Materials
Industry
Metals & Mining
Listed since
11 Jul 2001

Leadership

Pay as last reported

  • Robert RosnerChief Executive Officer, Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company is engaged in exploration and development of natural resource interests.
  • Headquartered in Henderson, Nevada, with an IPO date of 2001-07-11.
  • Focuses on research and development for treatments of brain diseases.

Weaknesses

  • The company is described as untrusted in the source description.
  • No specific financial data or performance metrics are provided.
  • The source description contains conflicting information about the company's industry.

Opportunities

  • Potential growth in the natural resource exploration sector.
  • Opportunity to expand research and development in neurological disease treatments.
  • Possible market expansion through platform technology for various neurological diseases.

Threats

  • Conflicting industry descriptions may confuse investors and stakeholders.
  • Untrusted source description could impact credibility and trustworthiness.
  • Lack of financial data may hinder investment decisions and market analysis.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.